O
Oliver Klein
Researcher at Ludwig Institute for Cancer Research
Publications - 19
Citations - 1561
Oliver Klein is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Ipilimumab & Vemurafenib. The author has an hindex of 13, co-authored 19 publications receiving 1329 citations. Previous affiliations of Oliver Klein include Austin Hospital & La Trobe University.
Papers
More filters
Journal ArticleDOI
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Alexander M. Menzies,Alexander M. Menzies,Douglas B. Johnson,S. Ramanujam,Victoria Atkinson,Annie Wong,John J. Park,Jennifer L. McQuade,Alexander N. Shoushtari,Katy K. Tsai,Zeynep Eroglu,Oliver Klein,Jessica C. Hassel,Jeffrey A. Sosman,Alexander Guminski,Alexander Guminski,Ryan J. Sullivan,Antoni Ribas,Matteo S. Carlino,Michael A. Davies,Shahneen Sandhu,Georgina V. Long,Georgina V. Long +22 more
TL;DR: The results support that anti-PD-1 can be administered safely and can achieve clinical benefit in patients with preexisting ADs or prior major irAEs with ipilimumab.
Journal ArticleDOI
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Allison Ackerman,Oliver Klein,David F. McDermott,Wei Wang,Nageatte Ibrahim,Donald P. Lawrence,Anasuya Gunturi,Keith T. Flaherty,F. Stephen Hodi,Richard F. Kefford,Alexander M. Menzies,Michael B. Atkins,Georgina V. Long,Ryan J. Sullivan +13 more
TL;DR: A retrospective analysis describes the outcomes of patients treated with either BRAFi before IT or IT before BRAFi, with or without trametinib.
Journal ArticleDOI
BRAF inhibitor activity in V600R metastatic melanoma
Oliver Klein,Arthur Clements,Alexander M. Menzies,Sandra A O'Toole,Richard F. Kefford,Richard F. Kefford,Georgina V. Long,Georgina V. Long +7 more
TL;DR: The experience suggests that patients with V600R BRAF mutations can be treated successfully with oral BRAF inhibitors, and molecular diagnostic assays should include detection of this type of mutation.
Journal ArticleDOI
Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.
Theo Nicholaou,Lisa M. Ebert,Ian D. Davis,Neil C Robson,Oliver Klein,Eugene Maraskovsky,Weisan Chen,Jonathan Cebon +7 more
TL;DR: The exceptional immunogenicity of this Ag coupled with its widespread distribution among many cancer types make it a very good vaccine candidate, with the potential to be used in vaccines against many types of malignancies.
Journal ArticleDOI
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Samantha Bowyer,Prashanth Prithviraj,Paul Lorigan,James Larkin,Grant A. McArthur,Victoria Atkinson,Michael Millward,Michael Millward,M. Khou,Stefan Diem,S. Ramanujam,Benjamin Y. Kong,Elizabeth Liniker,Alexander Guminski,Phillip Parente,Miles C. Andrews,Sagun Parakh,Jonathan Cebon,Georgina V. Long,Matteo S. Carlino,Matteo S. Carlino,Oliver Klein +21 more
TL;DR: Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports, but there appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.